investors image

US Biomarkers, Inc will work with Strategic Partners to facilitate drug development, patient stratification (companion diagnostics), and monitoring of drug efficacy with its MethDet® platform as the basis for analysis of biomarkers in cell-free plasma DNA to improve the success rate of drug development.

© Copyright 2017. US Biomarkers Inc. All Rights Reserved.